Merck & Co., Inc: Colorectal Neoplasms trials
The registry lists 25 Colorectal Neoplasms studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 19 have results posted.
Phase 1 10Phase 2 10Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)RecruitingNCT06428409Phase 1/2
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedNCT05600309Phase 3Results posted
- A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)CompletedNCT05064059Phase 3Results posted
- Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).CompletedNCT04895722Phase 2Results posted
- Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)CompletedNCT04776148Phase 3Results posted
- Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)CompletedNCT04456699Phase 3Results posted
- A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)TerminatedNCT03948763Phase 1Results posted
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)CompletedNCT03797326Phase 2Results posted
- Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)CompletedNCT03631407Phase 2Results posted
- Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)TerminatedNCT03515824Phase 1Results posted
- Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)CompletedNCT03374254Phase 1Results posted
- Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)TerminatedNCT02972034Phase 1Results posted
- Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)CompletedNCT02563002Phase 3Results posted
- Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)CompletedNCT02460198Phase 2Results posted
- A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedNCT01243762Phase 1Results posted
- Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)CompletedNCT00925015Phase 1Results posted
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)CompletedNCT00753415Phase 1Results posted
- Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)CompletedNCT00614393Phase 2Results posted
- A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)CompletedNCT00551213Phase 2Results posted
- Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)TerminatedNCT00423150Phase 2Results posted
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active, not recruitingNCT05239741Phase 3
- A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal TractWithdrawnNCT04195373Phase 1
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)TerminatedNCT00126451Phase 2
- MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)TerminatedNCT00099346Phase 1